Update of evidence- and consensus-based guidelines for the treatment of juvenile idiopathic arthritis (JIA) by the German Society of Pediatric and Juvenile Rheumatic Diseases (GKJR): New perspectives on interdisciplinary care.
Consensus guidelines
Juvenile idiopathic arthritis (JIA)
Management of JIA
Multidisciplinary care
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
received:
03
06
2022
revised:
26
09
2022
accepted:
27
09
2022
pubmed:
4
10
2022
medline:
26
11
2022
entrez:
3
10
2022
Statut:
ppublish
Résumé
New therapeutic strategies for juvenile idiopathic arthritis (JIA) have evolved within the past ten years, and as a result, an update of the 2011 recommendations of the German management guidelines was initiated. A systemic literature review was performed, overarching principles were proposed and pre-selected via an online survey followed by two multidisciplinary consensus conferences. Pharmacological and non-pharmacological treatments were discussed, statements were proposed and ultimately agreed upon by nominal group technique (NGT). 12 overarching therapeutic principles, as well as 9 recommendations on pharmacological and 5 on non-pharmacological treatments for JIA were agreed upon. This report summarizes the recent update of the interdisciplinary, consensus-based German guidelines on the management of JIA. The multi- and interdisciplinary participation of all caregivers was central for this patient-focused update. With these guidelines, physicians can choose an evidence-based approach, which allows better tailored treatment in this vulnerable cohort of children and adolescents.
Sections du résumé
BACKGROUND
New therapeutic strategies for juvenile idiopathic arthritis (JIA) have evolved within the past ten years, and as a result, an update of the 2011 recommendations of the German management guidelines was initiated.
METHODS
A systemic literature review was performed, overarching principles were proposed and pre-selected via an online survey followed by two multidisciplinary consensus conferences. Pharmacological and non-pharmacological treatments were discussed, statements were proposed and ultimately agreed upon by nominal group technique (NGT).
RESULTS
12 overarching therapeutic principles, as well as 9 recommendations on pharmacological and 5 on non-pharmacological treatments for JIA were agreed upon.
CONCLUSION
This report summarizes the recent update of the interdisciplinary, consensus-based German guidelines on the management of JIA. The multi- and interdisciplinary participation of all caregivers was central for this patient-focused update. With these guidelines, physicians can choose an evidence-based approach, which allows better tailored treatment in this vulnerable cohort of children and adolescents.
Identifiants
pubmed: 36191738
pii: S1521-6616(22)00224-8
doi: 10.1016/j.clim.2022.109143
pii:
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
109143Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest Dirk Holzinger: Novartis and Sobi (speaker fees). Christoph Deuter: research support by Affibody, Panoptes, Ursapharm; AbbVie, Alimera, Amgen, Novartis, Santen, Thea, UCB (speaker fees); consulting for Alimera. Anton Hospach: SOBI, Novartis (speaker fees). Prasad T. Oommen: Novartis (speaker fees and research support). Catharina Schuetz: Novartis (research support). Norbert Wagner: GlaxoSmithKline GmbH, Sanofi-Aventis Deutschland GmbH, RG Ärztefortbildung, Ges. für Information und Organization mbH, medupdate GmbH. Tim Niehues: UptoDate.com (authorship fees), Reimbursement of travel expenses from: EMA (European Medicines Agency), PENTA (Pediatric European Network for Treatment of AIDS), JIR (Juvenile Inflammatory Cohort). Michael Wachowsky: Biomarin Germany, Nuvasive Germany (reimbursement of travel expenses). Klaus Tenbrock: Novartis foundation, Pfizer (IIT), MBS (IIT) (research grants); Advisory Board for Novartis, Pfizer, GSK. Ariane Klein: Pfizer (speaker fees). Claas Hinze: Pfizer (reimbursement of travel expenses), Novartis (advisory board). Michael Jung: AquaFitness Akademie Hanau (consultancy). Ivan Foeldvari: Novartis, hexal, Medac, Lilly, Pfizer (advisory boards). Kirsten Minden: Pfizer, Novartis (consultancy), Abbvie, Novartis, Pfizer, Roche, Initiative for the child with rheumatism (speaker fees); Medac (honoraria). Tilmann Kallinich: Roche (speaker fees). Karen Baltruschat, Gerd Ganser, Johannes-Peter Haas, Hans-Iko Huppertz, Arnold Illhardt, Kirsten Mönkemöller, Sonja Mrusek, Ulrich Neudorf, Gregor Dückers, Matthias Schneider, Philipp Schoof, Angelika Thon, Susanne Bloedt, Michael Hofer declare no conflict of interest.